Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

Investing.com -- Shares of CVS Health Corp (NYSE:CVS), Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their ...

Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth ... in “excess” revenue over six years, the Federal Trade Commission said in a report on the drug middlemen.

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...